Filling in the gaps in PARP inhibitor-induced synthetic lethality

Filling in the gaps in PARP inhibitor-induced synthetic lethality

Tumors with loss of breast cancer type 1 susceptibility protein (BRCA1) are homologous recombination (HR) deficient and hypersensitive to poly(ADP-ribose) polymerase inhibitors (PARPi). However, these tumors may restore HR and acquire PARPi resistance via loss of end-protection of DNA double-strand...

Full description

Bibliographic Details
Main Authors: Mariana Paes Dias, Jos Jonkers
Format: Article
Language:English
Published: Taylor & Francis Group 2021-11-01
Series:Molecular & Cellular Oncology
Subjects:
brca1/2
parp inhibitors
drug resistance
ssdna gaps
Online Access:http://dx.doi.org/10.1080/23723556.2021.2010512

Internet

http://dx.doi.org/10.1080/23723556.2021.2010512

Similar Items